COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Extension Study of Talampanel for Amyotrophic Lateral Sclerosis (ALS) (ALSTAR OL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00982150
Recruitment Status : Terminated (Core study unsuccessful)
First Posted : September 23, 2009
Last Update Posted : August 26, 2013
Information provided by (Responsible Party):
Teva Pharmaceutical Industries

Brief Summary:
This will be an open label treatment extension phase in patients with ALS who have previously participated in the double blind, placebo-controlled ALS-TAL-201 study. This study will make talampanel treatment available to all subjects who completed the double blind placebo-controlled phase of ALS-TAL-201 study and where the investigator and patient consider it to be in the patient's interest to receive talampanel 50mg three times daily (tid). It will also enable the exploration of long-term safety and tolerability of talampanel 50mg tid.

Condition or disease Intervention/treatment Phase
Amyotrophic Lateral Sclerosis Drug: Talampanel Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 446 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multinational, Multicenter, Open Label Phase to Assess Tolerability and Safety of Talampanel 50mg Tid in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Study Start Date : September 2009
Actual Primary Completion Date : June 2010
Actual Study Completion Date : June 2010

Arm Intervention/treatment
Experimental: Talampanel
Talampanel 50mg tid
Drug: Talampanel
50mg capsules tid

Primary Outcome Measures :
  1. ALSFRS-R [ Time Frame: every 4 weeks ]

Secondary Outcome Measures :
  1. Vital Signs, ECG, Adverse Event Reports [ Time Frame: every 26 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must have completed 52 weeks of treatment of the double blind placebo-controlled phase of ALS-TAL-201.
  • Women must be postmenopausal, surgically sterile, or using adequate birth control methods.
  • Patients must be willing and able to give written informed consent prior to performing any open-label study procedures.

Exclusion Criteria:

  • Patients with ECG signs of Brugada syndrome and/ or complete or incomplete Right Bundle Branch Block
  • Patients using any of the following:

    • Chronic use of lithium carbonate
    • Chronic use of mecasermin (rhIGF-1)
    • Chronic use of minocycline
    • Chronic use of more than 600mg/day coenzyme Q10
    • Chronic use of any marketed drug, if its use was not clearly indicated for any underlying medical condition other than ALS (symptomatic drugs for ALS and supplements allowed)
  • Patients participating in any other investigational drug study and use of any other investigational drug
  • Patients taking drugs that may interact with Talampanel
  • Females who are pregnant or nursing.
  • Females of child-bearing potential who do not practice medically acceptable methods of contraception.
  • Any condition of the patient which the investigator feels may interfere with participation in the study.
Layout table for additonal information
Responsible Party: Teva Pharmaceutical Industries Identifier: NCT00982150    
Other Study ID Numbers: ALS-TAL-201-OL
First Posted: September 23, 2009    Key Record Dates
Last Update Posted: August 26, 2013
Last Verified: August 2013
Keywords provided by Teva Pharmaceutical Industries:
Open-Label Study
Amyotrophic Lateral Sclerosis
Additional relevant MeSH terms:
Layout table for MeSH terms
Motor Neuron Disease
Amyotrophic Lateral Sclerosis
Pathologic Processes
Neurodegenerative Diseases
Nervous System Diseases
Neuromuscular Diseases
Spinal Cord Diseases
Central Nervous System Diseases
TDP-43 Proteinopathies
Proteostasis Deficiencies
Metabolic Diseases